This study will estimate the absolute bioavailability of subcutaneously injected GS-5745, characterize the safety, tolerability, and pharmacokinetics (PK) of GS-5745 after subcutaneous (SC) injection and intravenous (IV) administration, and evaluate the formation of anti-GS-5745 antibodies after SC and IV administration.

Inclusion Criteria:

• In the opinion of the investigator, individuals must be in good general health based upon medical history and physical examination
• Females, of childbearing potential, and males must agree to utilize protocol specific contraception methods
• Screening laboratory evaluations must be within defined thresholds

Exclusion Criteria:

• Infection with hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV)
• Pregnant and lactating females
• History of clinically significant illness (including psychiatric or cardiac) or any other medical disorder that may interfere with individual treatment and/or adherence to the protocol